Utilization of Animal Studies to Determine the Effects and Human Risks of Environmental Toxicants (Drugs, Chemicals, and Physical Agents)

Pediatrics

Volumn 113, Issue 4 II, 2004, Pages 984-995

  Brent, Robert L ^a  

^a NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

Author keywords

Biologic plausibility; Deterministic; Environmental toxicology; In vitro systems; In vivo animal studies; Methods of evaluation; MOA (method of action); Pharmacodynamics; Pharmacokinetics; Stochastic; Threshold phenomenon; Toxicodynamics; Toxicokinetics

Indexed keywords

ALCOHOL; AMINOPTERIN; ANTICONVULSIVE AGENT; COUMARIN; DIETHYLSTILBESTROL; DIFLUNISAL; DRUG; ENVIRONMENTAL CHEMICAL; ETRETINATE; HYDANTOIN DERIVATIVE; ISOTRETINOIN; LEFLUNOMIDE; LITHIUM; MECLOZINE; MISOPROSTOL; PENICILLAMINE; POLYCHLORINATED BIPHENYL; RETINOL; TERATOGENIC AGENT; THALIDOMIDE; TRIMETHADIONE; TRIMETHOPRIM; VALPROIC ACID;

ANIMAL EXPERIMENT; BIOEQUIVALENCE; BIRTH DEFECT; CARCINOGENICITY; DEVELOPMENT; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EXPOSURE; DRUG MECHANISM; ECOTOXICOLOGY; ENVIRONMENTAL EXPOSURE; FEASIBILITY STUDY; GROWTH RETARDATION; IMMUNOTOXICITY; IN VITRO STUDY; IN VIVO STUDY; INFERTILITY; IONIZING RADIATION; MAXIMUM ALLOWABLE CONCENTRATION; MENTAL DEFICIENCY; NEUROTOXICITY; NONHUMAN; PEROXISOME; PHARMACODYNAMICS; PHARMACOKINETICS; PREDICTION; PRIORITY JOURNAL; REPRODUCTIVE TOXICITY; REVIEW; RISK ASSESSMENT; STILLBIRTH; STOCHASTIC MODEL; TERATOGENICITY; TERATOLOGY; TOXICITY TESTING; TOXICODYNAMICS; TOXICOKINETICS; TOXICOLOGY;

ADOLESCENT; ANIMALS; ANIMALS, NEWBORN; CHILD; FEMALE; FETUS; HAZARDOUS SUBSTANCES; HUMANS; INFANT, NEWBORN; MODELS, ANIMAL; PREGNANCY; TOXICOLOGY;

EID: 1842587382     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (128)

1. Brent RL. Evaluating the alleged teratogenicity of environmental agents. In: Brent RL, Beckman DA, eds. Clinics in Perinatology. Vol 13. Philadelphia, PA: WB Saunders; 1986:609-613
2. Brent RL. Protecting the public from teratogenic and mutagenic hazards. J Clin Pharmacol. 1972;12:61-70
3. Brent RL. Drug testing in animals for teratogenic effects: thalidomide in the pregnant rat. J Pediatr. 1964;64:762-770
4. Brent RL. The prediction of human diseases from laboratory and animal tests for teratogenicity, carcinogenicity and mutagenicity. In: Lasagna L ed. Controversies in Therapeutics. Philadelphia, PA: WB Saunders; 1980:134-150
5. Brent RL. Predicting teratogenic and reproductive risks in humans from exposure to various environmental agents using in vitro techniques and in vivo animal studies. Congenit Anom Kyoto. 1988;28(suppl):S41-S55
6. Christian MS, Brent RL. Teratogen update: evaluation of the reproductive and developmental risks of caffeine. Teratology. 2001;64:51-78
7. Brent RL. Book review: Scientific Frontiers in Developmental Toxicology and Risk Assessment by the National Research Council, National Academy of Sciences, National Academy Press, Washington, DC, 327 pp., 2000. Teratology. 2002;65:88-96
8. Brent RL. Teratogen update: reproductive risks of leflunomide (Avara); a pyrimidine synthesis inhibitor: counseling women taking leflunomide before or during pregnancy and men taking leflunomide who are contemplating fathering a child. Teratology. 2001;63:106-112
9. FDA, Progestational Drug Products for Human Use; Requirements for Labeling Directed to the Patient. Proposed Rules, Department of Health and Human Services, Public Health Service, Food and Drug Administration, 21 CFR Part 310 [Docket No. 99N-0188], 64 FR 17985, Tuesday, April 13, 1999; Federal Register, Vol. 64, No. 70
10. Physicians Desk Reference. 57th ed. Montvale, NJ: Medical Economics Co; 2003
11. Brent RL. Drugs and pregnancy: are the insert warnings too dire? Contemp OB-GYN. 1982;20:42-49
12. Brent RL. Utilization of developmental basic science principles in the evaluation of reproductive risks from pre- and post-conception environmental radiation exposures. Teratology. 1999;59:182-204
13. Friedman JM, Little BB, Brent RL, Cordero JF, Hanson JW, Shepard TH. Potential human teratogenicity of frequently prescribed drugs. Obstet Gynecol. 1990;75:594-599
14. Otake M. Schull WJ. In utero exposure to A-bomb radiation and mental retardation. A reassessment. Br J Radiol. 1984;57:409-414
15. Jensh RP, Brent RL, Vogel WH. Studies concerning the effects of low level prenatal x-irradiation on postnatal growth and adult behavior in the Wistar rat. Int J Radial Biol. 1986;50:1069-1081
16. Jensh RP, Brent RL, Vogel WH. Studies of the effect of 0.4 Gy and 0.6-Gy prenatal x-irradiation on postnatal adult behavior in the Wistar rat. Teratology. 1987;35:53-61
17. Jensh RP, Brent RL. Effects of 0.6-Gy postnatal neurophysiologic development in the Wistar rat. Proc Soc Exp Biol Med. 1986;181:611-619
18. Jensh RP, Brent RL. The effect of low-level prenatal x-irradiation on postnatal development in the Wistar rat. Proc Soc Exp Med. 1987;184:256-263
19. Brent RL, Beckman DA, Jensh RP. Relative radiosensitivity of fetal tissues. In: 1Lett JT, Altman KI, eds. Relative Radiation Sensitivities of Human Organ Systems. Vol 12. Orlando, FL: Academic Press; 1987:239-256
20. Jensh RP, Brent RL. The effects of prenatal x-irradiation in the 14th-18th days of gestation on postnatal growth and development in the rat. Teratology. 1988;38:431-441
21. Brent RL, Beckman DA, Jensh RP. The relationship of animal experiments in predicting the effects of intrauterine effects in the human. In: Kriegel H, Schmahl W, Gerber GB, Stieve FE, eds. Radiation Risks to the Developing Nervous System. New York, NY: Gustav Fisher; 1986:367-397
22. Miller RW. Discussion: severe mental retardation and cancer among atomic bomb survivors exposed in utero. Teratology. 1999;59:234-235
23. Jensh RP, Eisenman LM, Brent RL. Postnatal neurophysiologic effects of prenatal x-irradiation. Int J Radiat Biol. 1995;67:217-227
24. Schull WJ, Otake M. Cognitive function and prenatal exposure to ionizing radiation. Teratology. 1999;59:222-226
25. Brent RL. Evaluating the alleged teratogenicity of environmental agents. In: Brent RL, Beckman DA, eds. Clinics in Perinatology. Vol 13. Philadelphia, PA: WB Saunders; 1986:609-613
26. Schardein JL. Chemically Induced Birth Defects. New York, NY: Marcel Dekker; 2000:272-278
27. Bremer S, Pellizzer C, Adler S, Paparella M, de Lange J. Development of testing strategy for detecting embryotoxic hazards of chemicals in vitro by using embryonic stem cells. Altern Lab Anim. 2002;30(suppl 2):107-109
28. Done AK. Developmental pharmacology. Clin Pharmacol Ther. 1964;5:432-479
29. Hufeland CW. Lehrbuch der allgemeinen Heilkunde: Zwetze Auflage, aus dem System der praktischen Heilkunde besonders abgedruckt zum Gebrauch bei Vorlesungen, ed 2, Jena1830, F. Frommann
30. Dreyer B, Walker EWA. Therapeutical and pharmacological section: dosage of drugs, toxins and antitoxins. Proc R Soc Med. 1914;7:51-70
31. Behnke AR. The relation of lean body weight to metabolism and some consequent systematizations. Ann N Y Acad Sci. 1956;56:1095-1142
32. Friis-Hansen B. Changes in body water compartments during growth. Acta Paediatr. 1957;43:1-68
33. Friis-Hansen B. Body water compartments in children: changes during growth and related changes in body composition. Pediatrics. 1961;28:169-181
34. Weatherall JAC. Anesthesia in newborn animals. Br J Pharmacol. 1960;15:454-457
35. Cameron JA. Age and species differences among rodents in resistance to CO asphyxia. J Cell Comp Physiol. 1941;18:379-383
36. Cassin S, Herron CS Jr. Cerebral enzyme changes and tolerance to anoxia during maturation in the rabbit. Am J Physiol. 1961;201:440-442
37. Fazekas JF, Alexander FAD, Himwich HE. Tolerance of the newborn to anoxia. Am J Physiol. 1941;134:281-287
38. Reiss M, Haurowitz F. Uber das Verhalten Junger und Alter Tiere bei Enstickung, Klin. Kliniche Wachenshrift. 1929;1:743-744
39. Stafford A, Weatherall JA. The survival of young rats in nitrogen. J Physiol. 1962;153:457-472
40. Barrow EF. Age and resistance to ether in mice. Proc Soc Exp Biol Med. 1933;30:1290-1292
41. Mackenzie JB, Mackenzie CG. Production of pulmonary edema by thiourea in the rat and its relation to age. Proc Soc Exp Biol Med. 1943;54:34-37
42. Dieke SH, Richter CP. Acute toxicity of thiourea to rats in relation to age, diet, strain and species variation. J Pharmacol Exp Ther. 1945;83:195-202
43. Kent SP, Tucker ES III, Taranenko A. The toxicity of chloramphenicol in newborn versus adult mice. Am J Dis Child. 1960;100:400-401
44. Michael AF, Giesel RG, Sutherland JM. Chloramphenicol toxicity in newborn rats. Antibiotics Chemother. 1960;10:368-370
45. Raynsford G. Technique of comparing acute toxicity in infants vs. adult rats. A comparative study of three antibiotics. Am J Dis Child. 1963;105:323-328
46. Selevan S, Kimmel CA, Mendola P. Identifying critical windows of exposure for children's health. Environ Health Perspect. 2000;108(suppl 3):451-455
47. Hunt VR, Smith MK, Worth D, eds. Environmental Factors in Human Growth and Development. Banbury Report. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory; 1982
48. Kimmel CA, Kavlock RJ, Francis EZ. Animal models for assessing developmental toxicity. In: Guzelian PS, Henry CJ, Olin SS, eds. Similarities and Differences Between Children and Adults: Implications for Risk Assessment. Washington, DC: ILSI Press; 1992:43
49. Daniels JL, Olshan AF, Savitz DA. Pesticides and childhood cancers. Environ Health Perspect. 1997;105:1068-1077
50. Needleman HL, Schell A, Bellingler D, Leviton A, Allred EN. The long-term effects of exposure to low doses of lead in childhood. An 11-year follow-up report. N Engl J Med. 1990;322:83-88
51. Miller RW. Special susceptibility of the child to certain radiation-induced cancers. Environ Health Perspect. 1995;103(suppl 6):41-44
52. Wadsworth ME, Kuh DJ. Childhood influences on adult health: a review of recent work from the British 1946 national birth cohort study, the MRC National Survey of Health and Development. Paediatr Perinat Epidemiol. 1997;11:2-20
53. Pryor JL, Hughes C, Foster W, Hales BF, Robaire B. Critical windows of exposure for children's health: the reproductive system in animals and humans. Environ Health Perspect. 2000;108(suppl 3):433-438
54. Gray JB, Gangolii SD. Aspects of the testicular toxicity of phthalate esters. Environ Health Perspect. 1986;65:229-235
55. Sjorberg P, Lindqvist NG, Ploen L. Age-dependent response of the rat testes to di(2-ethylhexyl)phthalate. Environ Health Perspect. 1986;65:237-242
56. Dostal LA, Chapin RE, Stefanski SA, Harris MW, Schwetz BA. Testicular toxicity and reduced Sertoli cell numbers in neonatal rats by di(2-ethylhexyl) phthalate and recovery of fertility as adults. Toxicol Appl Pharmacol. 1988;95:104-121
57. Lui EM, Wysocki GP. Reproductive tract defects induced in adult male rats by postnatal 1,2-dibromo-3-chlorpropane exposure. Toxicol Appl Pharmacol. 1987;15:299-314
58. Warren DW, Ahmad N, Rudeen PK. The effects of fetal exposure to 1,2-dibromo-3-chloropropane on adult reproductive function. Biol Reprod. 1988;39:707-716
59. Lemasters GK, Perreault SD, Hales BF, et al. Workshop to identify critical windows of exposure for children's health: reproductive health in children and adolescents work group summary. Environ Health Perspect. 2000;108(suppl 3):505-509
60. Kelce WR, Zirkin BR, Ewing LL. Immature rat Leydig cells are intrinsically less sensitive than adult Leydig cells to ethane dimethanesulfonate. Toxicol Appl Pharmacol. 1991;111:189-200
61. Brown CD, Forman CL, McEuen SF, Miller MG. Metabolism and testicular toxicity of 1,3-dinitrobenzene in rats of different ages. Fundam Appl Toxicol. 1994;23:439-446
62. Flaws JA, Salyers KL, Sipes IG, Hoyer PB. Reduced ability of rat preantral ovarian follicles to metabolize 4-vinyl-1-cyclohexene diepoxide in vitro. Toxicol Appl Pharmacol. 1994;126:286-294
63. Brouwer A, Ahlborg UG, Van Den Berg M, et al. Functional aspects of developmental toxicity of polyhalogenated aromatic hydrocarbons in experimental animals and human infants. Eur J Pharmacol. 1995;293:1-40
64. Morreale de Escobar G, Obregon MJ, Calvo R, Pedraza P, Escobar del Rey F. Iodine deficiency, the hidden scourge: the rat model of human neurological cretinism. In: Hendrich CE, ed. Recent Research Development in Neuroendocrinology-Thyroid Hormone and Brain Maturation. Kerala State, IN: Research Signpost; 1997:66-70
65. Donati L, Antonelli A, Bertoni F, et al. Clinical picture of endemic cretinism in central Apennines (Montefeltro). Thyroid. 1992;2:283-290
66. Miller RW. How environmental efforts on child health are recognized. Pediatrics. 1974;53(suppl):792-796
67. Miller RW. Radiation injury. In: Behrman R, ed. Nelson's Textbook of Pediatrics. 14th ed. Philadelphia, PA: WB Saunders; 1996:769-770
68. Preston DL, Mattsson A, Homberg E, Shore R, Hildreth NG, Boice JD Jr. Radiation effects of breast cancer risk: a pooled analysis of eight cohorts. Radiat Res. 2002;158:220-235
69. Pierce DA, Shimizu Y, Preston D, Vaeth M, Mabuchi K. Studies of the mortality of atomic bomb survivors. Report 12, Part 1. Cancer: 1950-1990. Radiat Res. 1996;146:1-27
70. McKinney JD, Waller CL. Polychlorinated biphenyls as hormonally active structural analogues. Environ Health Perspect. 1994;102:290-297
71. Maier WE, Kodavanti PR, Harry GJ, Tilson HA. Sensitivity of adenosine triphosphatases in different brain regions to polychlorinated biphenyl congeners. J Appl Toxicol. 1994;14:225-229
72. McKinney JD, Chae K, Oatley SJ, Blake CCF. Molecular interactions of toxic chlorinated dibeno-p-dioxins and dibenzofurans with thyroxine binding prealbumin. J Med Chem. 1985;28:375-381
73. Ness DK, Schantz SL, Moshtaghian J, Hansen LG. Effects of perinatal exposure to specific PCB congeners on thyroid hormone concentrations and thyroid histology in the rat. Toxicol Lett. 1993;68:311-323
74. Koopman-Esseboom C, Morse DC, Weisglas-Kuperus N, et al. Effects of dioxins and polychlorinated biphenyls on thyroid hormone status of pregnant women and their infants. Pediatr Res. 1994;36:468-473
75. Morse DC, Wehler EK, Wesseling W, Koeman JH, Brouwer A. Alterations in rat brain thyroid hormone status following pre- and postnatal exposure to polychlorinated biphenyls (Aroclor 1254). Toxicol Appl Pharmacol. 1996;136:269-279
76. Holladay S, Smialowicz RJ Development of the murine and human immune system: differential effects of immunotoxicants depend on time of exposure. Environ Health Perspect. 2000;108(suppl 3):463-473
77. Rodier PM, Reynolds SS. Morphological correlates of behavioral abnormalities in experimental congenital brain damage. Exp Neurol. 1977;57:81-93
78. Rodier PM. Chronology of neuron development. Animal studies and their clinical implications. Dev Med Child Neurol. 1980;22:525-545
79. Rice D, Barone S Jr. Critical periods of vulnerability for the developing nervous system: evidence from humans and animal models. Environ Health Perspect. 2000;108(suppl 3):511-533
80. Weiss B, Landrigan PJ. The developing brain and the environment: an introduction. Environ Health Perspect. 2000;108(suppl 3):373-374
81. Stromland K, Nordin V, Miller M, Akerstrom B, Gilberg C. Autism in the thalidomide embryopathy: a population study. Dev Med Child Neurol. 1994;36:351-356
82. Rodier PM, Ingram JL. Tisdale B, Nelson S, Romano J. Embryological origin for autism: developmental anomalies of the cranial nerve motor nuclei. J Comp Neurol. 1996;370:247-261
83. Otis EM, Brent RL. Equivalent ages in mouse and human embryos. Anat Rec. 1954;12:33-65
84. Adams J, Barone S Jr, LaMantia A, et al. Workshop to identify critical windows of exposure for children's health: Neurobehavioral Work Group Study. Environ Health Perspect. 2000;108(suppl 3):535-544
85. Jernigan TL, Trauner DA, Hesselink JR, Tallal PA. Maturation of human cerebrum observed in vivo during adolescence. Brain. 1991;114:2037-2049
86. Van Eden CG, Kros JM, Uylings HBM. The development of the rat prefrontal cortex: its size and development of connections with thalamus, spinal cord and other cortical areas. In: Uylings HBM, vanEden CG, DeBruin JPC, Comer MA, Feenstra MGP, eds. The Prefrontal Cortex: Its Structure, Function, and Pathology. Vol 85. Amsterdam, the Netherlands: Elsevier; 1999:169-183
87. Zecevic N, Rakic P. Synaptogenesis in monkey somatosensory cortex. Cereb Cortex. 1991;1:510-523
88. Lewis DA. Development of the prefrontal cortex during adolescence: insights into vulnerable neural circuits in schizophrenia. Neuropsychopharmacology. 1997;16:385-398
89. Anderson SL, Dumont NL, Teicher MH. Developmental differences in dopamine synthesis inhibition by (+)-7-OH-DPAT. Naunyn Schmeidelbergs Arch Pharmacol. 1997;356:173-181
90. Teicher MH, Barbara NI, Gelbard HA, et al. Developmental differences in acute ingrostriatal and mesocorticolimbic system response to haloperidol. Neuropsychopharmacology. 1993;9:147-156
91. Benes FM. Myelination of cortical-hippocampal relays during late adolescence. Schizophr Bull. 1989;15:585-593
92. Dumas TC, Foster TC. Late developmental changes in the ability of adenosine Al receptors to regulate synaptic transmission in the hippocampus. Dev Brain Res. 1998;105:137-139
93. Choi S, Weisberg SN, Kellogg CK. Control of endogenous norepinephrine release in the hypothalamus of male rat changes over adolescent development. Dev Brain Res. 1997;98:134-141
94. Salimov RM, McBride WJ, McKinzie DL, Lumeng L, Li TK. Effects of ethanol consumption by adolescent alcohol-preferring P rats on subsequent behavioral performance in the cross-maze and slip funnel tests. Alcohol. 1996;13:297-300
95. Zahm SH, Devesa SS. Childhood cancer: overview of incidence trends and environmental carcinogens. Environ Health Perspect. 1995;103:177-184
96. Byrne J. Long-term genetic and reproductive effects of ionizing radiation and chemotherapeutic agents on cancer patients and their off-spring. Teratology. 1999;59:210-215
97. Dybing E, Sanner T. Species differences in chemical carcinogenesis of the thyroid gland, kidney and urinary bladder. IARC Sci Publ. 1999;147:15-32
98. Grisham JW. Interspecies comparisons of liver carcinogenesis: implications for cancer risk assessment. Carcinogenesis. 1997;19:59-81
99. Hengstler JG, Van der Burg B, Steinberg P, et al. Interspecies differences in cancer susceptibility and toxicity. Drug Metab Rev. 1999;31:917-970
100. Astill BD. Metabolism of DEHP: effects of prefeeding and dose variation, and comparative studies in rodents and the cynomolgus monkey (CMA studies). Drug Metab Rev. 1989;21:35-53
101. Elcombe CR, Mitchell AM. Peroxisome proliferation due to di(2-ethylhexyl)phthalate (DEHP): species differences and possible mechanism. Environ Health Perspect. 1986;70:211-219
102. Goll V, Alexandre E, Viollon-Abadie C, Nicod L, Jaeck D, Richert L. Comparison of the effects of various peroxisome proliferators on peroxisomal enzyme activities, DNA synthesis, and apoptosis in rat and human hepatocyte cultures. Toxicol Appl Pharmacol. 1999;160:21-32
103. Hasmall SC, James NH, McDonald N, et al. Suppression of apoptosis and induction of DNA synthesis in vitro by the phthalate plasticizers monoethylhexylphthalate (MEHP) and diisononylphthalate (DINP): a comparison of rat and human hepatocytes in vitro. Arch Toxicol. 1999;73:451-456
104. Hasmall SC, James NH, Macdonald N, Soames AR, Roberts RA. Species differences in response to diethylhexylphthalate (DEHP): suppression of apoptosis, induction of DNA synthesis and PPAR-mediated gene expression. Arch Toxicol. 2000;74:85-91
105. Huber WW, Kraupp-Grasl B, Schulte-Hermann R. Hepatocarcinogenic potential of DEHP in rodents and its implications on human risk. Crit Rev Toxicol. 1996;26:365-481
106. Kedderis GL, Batra R. Species differences in the hydrolysis of 2-cyanoethylene oxide, the epoxide metabolite of acrylonitrile. Carcinogenesis. 1993;14:685-689
107. Kurata Y, Kidachi F, Yokoyama M, Toyota N, Tsuchitani M, Katoh M. Subchronic toxicity of di(2-ethylhexyl)phthalate in common marmosets lack of hepatic peroxisome proliferation, testicular atrophy of pancreatic acinar cell hyperplasia. Toxicol Sci. 1998;42:49-56
108. Woodyatt NJ, Lambe KG, Myers KA, Tugwood JD, Roberts RA. The peroxisome proliferator (PP) response element upstream of the human acyl CoA oxidase gene is inactive among a sample human population: significance for species differences in response to PPs. Carcinogenesis. 1999;20:369-372
109. Ashby J, Brady A, Elcombe CR, et al. Mechanistically-based human hazard assessment of peroxisome proliferator induced hepatocarcinogenesis. Hum Exp Toxicol. 1994;13(suppl 2):S1-S117
110. Conway JG, Tomaszewski KE, Olson MJ, Cattley RC, Marsman DS, Popp JA. Relationship of oxidative damage to carcinogenicity with peroxisome proliferators di(2-eythlhexyl)phthalate (DEHP) and Wy-14643. Carcinogenesis. 1989;10:513-520
111. David RM, Moore MR, Cifone MA, Finney DC, Guest D. Chronic peroxisome proliferation and hepatomegaly associated with the hepatocellular tumorigenesis of di(2-ethylhexyl)phthalate and the effects of recovery. Toxicol Sci. 1999;50:195-205
112. Kluwe WM. The nephrotoxicity of low molecular weight halogenated alkane solvents, pesticides, and chemical intermediates. In: Hook JB, ed. Toxicology of the Kidney. New York, NY: Raven Press; 1981:179-226
113. Kluwe WM. The carcinogenicity of dietary di(2-ethylhexyl) phthalate (DEHP) in Fischer 344 rats and B6C3F1 mice. J Toxicol Environ Health. 1982;10:797-815
114. Lawrence JW, Li Y, Chen S, et al. Differential gene regulation in human versus rodent hepatocytes by peroxisome proliferator-activated receptor (PPAR) alpha. PPARalpha fails to induce peroxisome proliferation-associated genes in human cells independently of the level of receptor expression. J Biol Chem. 2001;276:31521-31527
115. Marsman DS, Cattley RC, Conway JG, Popp JA. Relationship of hepatic peroxisome proliferation and replicative DNA synthesis to the hepatocarcinogenicity of the peroxisome proliferators di(2ethylhexyl)phthalate and [4-chloro-6-(2,3-xylidino)-2-pryimidinylthio] acetic acid (Wy-14, 643) in rats. Cancer Res. 1988;48:6739-6744
116. Mukherjee R, Jow L, Noonan D, McDonnell DP. Human and rat peroxisome proliferator activated receptors (PPARs) demonstrate similar tissue distribution but different responsiveness to PPAR activators. J Steroid Biochem Mol Biol. 1994;51:157-166
117. Palmer CN, Hsu MH, Griffin KJ, Raucy JL, Johnson EF. Peroxisome proliferator activated receptor-alpha expression in human liver. Mol Pharmacol. 1998;53:14-22
118. Schmid P, Schlatte C. Excretion and metabolism of di(2-ethylhexy)-phthalate in man. Xenobiotica. 1985;15:251-256
119. Short RD, Robinson EC, Lington AW, Chin AE. Metabolis and peroxisome proliferation studies with di(2-ethylhexy)phthalate in rats and monkeys. Toxicol Ind Health. 1987;3:185-194
120. Ames BN, Gold LS. Chemical carcinogenesis: too many rodent carcinogens. Proc Natl Acad Sci U S A. 1990;87:7772-7776
121. Cohen SM. Role of cell proliferation in regenerative and neoplastic disease. Toxicol Lett. 1995;82-83:15-21
122. Farber E. Cell proliferation as a major risk factor for cancer: a concept of doubtful validity. Cancer Res. 1995;55:3759-3762
123. Melnick RL, Kohn MC, Anderson D, Herbst A. Regenerative hyperplasia is not required for liver tumor induction in female B6C3F1 mice exposed to trihalomethanes. Toxicol Appl Pharmacol. 1998;148:137-147
124. Preston-Martin S, Pike MC, Ross RK, Jones PA, Henderson BE. Increased cell division as a cause of human cancer. Cancer Res. 1990;50:7415-7421
125. Smith-Oliver T, Butterworth BE. Correlation of the carcinogenic potential of di(2-ethylhexy)-phthalate (DEHP) with induced hyperplasia rather than with genotoxic activity. Mutat Res. 1987;188:21-28
126. Lambe KG, Woodyatt NJ, Macdonald N, Chevalier S, Roberts RA. Species differences in sequence and activity of the peroxisome proliferator response element (PPRE) within the acyl CoA oxidase gene promoter. Toxicol Lett. 1999;110:119-127
127. Cohen SM. Cell proliferation and carcinogenesis. Drug Metab Rev. 1998;30:339-357
128. Cohen SM. Calcium phosphate-containing urinary precipitate in rat urinary carcinogenesis. IARC Sci Publ. 1999;147:175-189